Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord mesenchymal stem cells for inherited neuromuscular disorders
IRCT20200426047213N1Phase 3Completed
- Sponsor
- Islamic Azad University, Tehran Medical Sciences Branch
- Start
- Oct 2019
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of human umbilical cord mesenchymal stem cells in dystrophinopathy, spinal muscular atrophy (SMA), congenital myopathy and 4 more (2 arms), sponsored by Islamic Azad University, Tehran Medical Sciences Branch. Primary endpoint: Muscle strength enhancement. Started Oct 2019; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
dystrophinopathyspinal muscular atrophy (SMA)congenital myopathycongenital myasthenic syndrome (CMS)Charcot-Marie-Tooth disease (CMT)
Beyond the preview
Go deeper on IRCT20200426047213N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200426047213N1.